跳到内容

重型β地中海贫血

药物诱导胎儿血红蛋白合成

羟基脲治疗

Efficacy of hydroxyurea in providing transfusion independence in β-thalassemia. (打开新窗口)

Ansari SH, Shamsi TS, Ashraf M, Perveen K, Farzana T, Bohray M, Erum S, Mehboob T.

来源‎: J Pediatr Hematol Oncol 2011;33(5):339-43.

检索‎: PubMed 21602718

DOI码‎: 10.1097/MPH.0b013e31821b0770

https://www.ncbi.nlm.nih.gov/pubmed/21602718 (打开新窗口)

Hydroxyurea treatment in β-thalassemia patients: to respond or not to respond? (打开新窗口)

Banan M.

来源‎: Ann Hematol 2013;92(3):289-99.

检索‎: PubMed 23318979

DOI码‎: 10.1007/s00277-012-1671-3

https://www.ncbi.nlm.nih.gov/pubmed/23318979 (打开新窗口)

Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia. (打开新窗口)

Bradai M, Pissard S, Abad MT, Dechartres A, Ribeil JA, Landais P, de Montalembert M.

来源‎: Transfusion 2007;47(10):1830-6.

检索‎: PubMed 17880608

DOI码‎: 10.1111/j.1537-2995.2007.01399.x

https://www.ncbi.nlm.nih.gov/pubmed/17880608 (打开新窗口)

Hydroxyurea increases hemoglobin F levels and improves the effectiveness of erythropoiesis in beta-thalassemia/hemoglobin E disease. (打开新窗口)

Fucharoen S, Siritanaratkul N, Winichagoon P, Chowthaworn J, Siriboon W, Muangsup W, Chaicharoen S, Poolsup N, Chindavijak B, Pootrakul P, Piankijagum A, Schechter AN, Rodgers GP.

来源‎: Blood 1996;87(3):887-92.

检索‎: PubMed 8562958

https://www.ncbi.nlm.nih.gov/pubmed/8562958 (打开新窗口)

Genotype-phenotype relationship of patients with β-thalassemia taking hydroxyurea: a 13-year experience in Iran. (打开新窗口)

Karimi M, Haghpanah S, Farhadi A, Yavarian M.

来源‎: Int J Hematol 2012;95(1):51-6.

检索‎: PubMed 22180324

DOI码‎: 10.1007/s12185-011-0985-6

https://www.ncbi.nlm.nih.gov/pubmed/22180324 (打开新窗口)

Clinical experience with fetal hemoglobin induction therapy in patients with β-thalassemia. (打开新窗口)

Musallam KM, Taher AT, Cappellini MD, Sankaran VG.

来源‎: Blood 2013;121(12):2199-212.

检索‎: PubMed 23315167

DOI码‎: 10.1182/blood-2012-10-408021

https://www.ncbi.nlm.nih.gov/pubmed/23315167 (打开新窗口)

A randomised double-blind placebo-controlled clinical trial of oral hydroxyurea for transfusion-dependent β-thalassaemia. (打开新窗口)

Yasara N, Wickramarathne N, Mettananda C, Silva I, Hameed N, Attanayaka K, Rodrigo R, Wickramasinghe N, Perera L, Manamperi A, Premawardhena A, Mettananda S

来源‎: Sci Rep. 2022;12(1):2752.

检索‎: PubMed 35177777

DOI码‎: 10.1038/s41598-022-06774-8

https://pubmed.ncbi.nlm.nih.gov/35177777/ (打开新窗口)

Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients. (打开新窗口)

Yavarian M, Karimi M, Bakker E, Harteveld CL, Giordano PC.

来源‎: Haematologica 2004;89(10):1172-8.

检索‎: PubMed 15477200

https://www.ncbi.nlm.nih.gov/pubmed/15477200 (打开新窗口)

Hydroxyurea therapy in 49 patients with major beta-thalassemia. (打开新窗口)

Zamani F, Shakeri R, Eslami SM, Razavi SM, Basi A.

来源‎: Arch Iran Med 2009;12(3):295-7.

检索‎: PubMed 19400608

https://www.ncbi.nlm.nih.gov/pubmed/19400608 (打开新窗口)

重组人促红细胞生成素(单用或跟其他药物联合使用)

Induction of fetal hemoglobin synthesis with recombinant human erythropoietin in anemic patients with heterozygous beta-thalassemia during pregnancy. (打开新窗口)

Breymann C, Fibach E, Visca E, Huettner C, Huch A, Huch R.

来源‎: J Matern Fetal Med 1999;8(1):1-7.

检索‎: PubMed 10052837

DOI码‎: 10.1002/(SICI)1520-6661(199901/02)8:1<1::AID-MFM1>3.0.CO;2-O

https://www.ncbi.nlm.nih.gov/pubmed/10052837 (打开新窗口)

Treatment of beta-thalassemia patients with recombinant human erythropoietin: effect on transfusion requirements and soluble adhesion molecules. (打开新窗口)

Chaidos A, Makis A, Hatzimichael E, Tsiara S, Gouva M, Tzouvara E, Bourantas KL.

来源‎: Acta Haematol 2004;111(4):189-95.

检索‎: PubMed 15153710

DOI码‎: 10.1159/000077551

https://www.ncbi.nlm.nih.gov/pubmed/15153710 (打开新窗口)

Fetal globin induction--can it cure beta thalassemia? (打开新窗口)

Perrine SP.

来源‎: Hematology Am Soc Hematol Educ Program 2005:38-44.

检索‎: PubMed 16304357

DOI码‎: 10.1182/asheducation-2005.1.38

https://www.ncbi.nlm.nih.gov/pubmed/16304357 (打开新窗口)